Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep Medicinesierra health and life sleep apnea Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentsierra health and lifePolicy 2026T0525TT

    Obstructive and Central Sleep Apnea Treatment

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026T0525TT alerts

    Get alerted when Policy 2026T0525TT changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity and coverage stance for non‑surgical and surgical treatments of obstructive and central sleep apnea for UnitedHealthcare Commercial and Individual Exchange plans. Affects providers submitting prior authorization and documentation for sleep apnea therapies and devices.

    Policy Summary
    Payersierra health and life
    PolicyObstructive and Central Sleep Apnea Treatment
    Policy CodePolicy 2026T0525TT
    Change TypeTemplate update (no material clinical changes)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionVerify member-specific benefits and document prior CPAP failure/intolerance and polysomnography-confirmed AHI when requesting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Template Update noted in Policy History/Revision Information for 01/01/2026.

    AHI ≥15surgical treatment threshold
    ≤40hypoglossal BMI limit
    E0486coding highlight
    UnprovenCSA device stance
    50-90%MMA AHI improvement

    Coverage Criteria and Evidence-Based Stance

    Adult surgical OSA coverage

    Proven and medically necessary in adults when ALL of the following are met:

    Adult surgical OSA criteria: Moderate to severe OSA (AHI or RDI ≥ 15) as determined by attended polysomnography; excessive daytime sleepiness documented (Epworth Sleepiness Scale > 10 or other validated tool); prior trial of PAP therapy that resulted in no therapeutic efficacy or documented patient refusal/intolerance; procedure-specific anatomic criteria when applicable (for MMA: evidence of craniofacial/maxillomandibular deficiency; for mandibular osteotomy: retrolingual or lower pharyngeal obstruction).AHI/RDI ≥ 15; ESS > 10

    Supports coverage of UPPP, mandibular osteotomy (MO), and maxillomandibular advancement (MMA) in adults when all items are satisfied.

    Implantable hypoglossal nerve stimulation (adults)

    Proven and medically necessary in an adult patient with moderate to severe OSA when ALL of the following are met:

    Adult hypoglossal device:
    Policy Summary
    Payersierra health and life
    PolicyObstructive and Central Sleep Apnea Treatment
    Policy CodePolicy 2026T0525TT
    Change TypeTemplate update (no material clinical changes)
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionVerify member-specific benefits and document prior CPAP failure/intolerance and polysomnography-confirmed AHI when requesting authorization.
    SourceLink
    On This Page
    Coverage Criteria and Evidence-Based StanceProvider Requirements, Prior Authorization & DocumentationApplicable Codes, Thresholds and Billing GuidanceClinical Background, Definitions & Evidence ContextPolicy Updates and Revision Notes
    Body mass index ≤ 40 kg/m2; AHI ≥ 15 and ≤ 100 on attended polysomnography; total AHI comprised of < 25% central plus mixed apneas; absence of complete concentric collapse of the soft palate confirmed by drug‑induced sleep endoscopy (DISE); prior PAP therapy resulted in no therapeutic efficacy or there is documented PAP intolerance or refusal; device implantation and use in accordance with FDA labeling and guidance (including absence of contraindicated anatomy).
    BMI ≤ 40; AHI 15–100; central+mixed <25%

    Patient selection should follow device labeling (Inspire UAS) including DISE assessment and documentation of prior PAP failure/intolerance; prior authorization typically required and device must be FDA‑approved for the indicated population.

    Implantable hypoglossal nerve stimulation (adolescents with Down syndrome)

    Proven and medically necessary in adolescents aged 10–18 years with Down syndrome when ALL of the following are met:

    Adolescent hypoglossal device: Diagnosis of severe OSA by attended polysomnography (AHI ≥ 10 and RDI ≤ 50); BMI less than the 95th percentile for age; total AHI < 25% central plus mixed apneas; prior adenotonsillectomy contraindicated or not effective; confirmed failure or intolerance of PAP despite attempts to optimize compliance; no tracheostomy during sleep; absence of complete concentric collapse of the soft palate on DISE; individual and caregiver decline of MMA when applicable; use consistent with FDA pediatric Down syndrome indication and device labeling.AHI ≥10 and RDI ≤50; BMI <95th percentile

    Follows the FDA expanded pediatric Down syndrome indication and requires documentation of prior therapies and DISE.

    Removable oral appliances

    Non-surgical removable oral appliances are proven and medically necessary when ALL of the following are met:

    Oral appliance therapy: Obstructive sleep apnea documented by an appropriate sleep study (attended polysomnography or validated home sleep apnea testing); face-to-face evaluation and diagnosis by a qualified physician (MD or DO) trained in sleep medicine or an APP under direct supervision prior to OAT initiation; treating physician or APP documents recommendation for an oral appliance; when used as an alternative to PAP, documentation of prior PAP failure, intolerance, or patient refusal; appliance is custom‑fabricated and titratable and provided by a qualified dental provider with documented follow-up and objective testing to confirm efficacy per guideline recommendations.diagnostic sleep study required

    InterQual criteria referenced for detailed removable oral appliance medical necessity; custom titratable devices preferred over prefabricated devices per AASM/AADSM guidance.

    Non-PAP device coverage considerations

    Coverage considerations and evidence summaries for non-PAP therapies and devices

    Non‑PAP device overview: Non‑PAP therapies (positional devices, nasal dilators/EPAP, intraoral electrical stimulation, and other positional/oral devices) have heterogeneous evidence; some devices may reduce AHI or symptoms in select patients but are generally inferior to CPAP and evidence quality ranges from low to very low. Coverage decisions should reflect device‑specific evidence and patient selection.

    Providers should document prior CPAP trial when appropriate and confirm device applicability to the patient's OSA phenotype.

    Positional therapy: Positional devices (vibratory trainers, pillows, vests) may improve AHI in positional OSA and can have better short‑term adherence than CPAP, but CPAP is more effective overall and long‑term efficacy is uncertain.non‑supine AHI < 20 or positional dependence per studies

    Hayes and Cochrane reviews report low to moderate quality evidence with short follow‑up.

    Nasal dilators / EPAP: Nasal dilators and intranasal EPAP devices (eg, Provent) show mixed trial results; some RCTs report AHI reductions versus sham, but EPAP is inferior to CPAP and long‑term responder data are limited.mild–severe OSA in trials; device‑specific inclusion criteria

    Short follow‑up and manufacturer‑sponsored trials limit certainty.

    Intraoral awake electrical stimulation: Devices (eg, eXciteOSA, Apone‑Stim) have limited low‑quality evidence showing symptom and AHI improvements in mild OSA or snoring; comparative RCTs and long‑term outcomes are lacking.mild OSA in available studies

    Systematic reviews identify very low to low quality evidence; further RCTs needed.

    Central Sleep Apnea (CSA) and removable oral appliances: Removable oral appliances are not supported by quality evidence for the treatment of central sleep apnea and are not appropriate for CSA management.

    Oral appliances target anatomic obstruction and lack evidence for neurologic CSA.

    Coverage considerations by therapy type

    Coverage stance and supporting criteria by intervention category

    Oral appliance therapy (custom, titratable): Considered for patients with OSA who are intolerant of CPAP or prefer alternative therapy; must be prescribed by a sleep physician and fitted by a qualified dentist with documented objective follow-up testing to confirm efficacy.sleep physician diagnosis of OSA; prior CPAP failure/intolerance when applicable

    AASM/AADSM/AAOMS guidance supports use in mild‑to‑moderate OSA and selected severe cases after CPAP failure.

    Intraoral awake neuromuscular electrical stimulation devices: Evidence from small studies and a systematic review suggests potential benefit for snoring and mild OSA, but lack of sham/comparator trials and low quality evidence warrant caution in coverage.mild OSA in studies

    Device names include Apone‑Stim and eXciteOSA; additional high‑quality trials required.

    Devices with no quality evidence: Mandibular vertical repositioning devices, morning repositioning devices, epigenetic appliances, and ALF appliances lack quality evidence and are unsupported for coverage.no published quality studies

    Policy explicitly identifies these device classes as unsupported.

    Surgical interventions - general: Surgery may be appropriate for patients with major anatomic upper airway obstruction or when CPAP is intolerable; overall evidence quality for many surgeries is low and patient selection, anatomic localization, and counseling on expected benefit and risks are essential.documented anatomic obstruction or documented CPAP intolerance

    AASM task force supports referral for surgical consultation in appropriate patients.

    Maxillomandibular advancement (MMA): MMA demonstrates consistent and substantial reductions in AHI and symptomatic improvement across multiple studies and meta‑analyses and is considered an effective option for appropriately selected patients, particularly for severe OSA when other therapies are not tolerated.surgical candidate selection per reviewed studies (eg, prior CPAP failure, anatomic deficiency)

    Meta‑analyses report high proportions of patients with improved AHI/RDI after MMA.

    Simple/minimally invasive palatal/upper‑airway surgeries: Procedures such as palatal implants, LAUP, UPPP (as a sole therapy), and RFA may improve AHI or symptoms in select patients but are generally not curative; evidence is mixed and modest benefit should be communicated to patients.specific patient anatomy and prior therapy failure

    Counsel on limited/variable efficacy and potential complications; NICE and reviews note limited evidence for palatal implants.

    HNS/UAS (Hypoglossal Nerve Stimulation) — trial-aligned coverage

    Evidence supports HNS/UAS for select CPAP-intolerant patients with moderate-to-severe OSA when criteria similar to trials are met:

    HNS candidate criteria (trial-like): Documented moderate‑to‑severe OSA with baseline AHI in the trial/clinical program ranges (eg, median baseline AHI ~29 in STAR); prior documented trial of PAP therapy with documented failure, intolerance, or refusal; anatomic assessment excluding complete concentric collapse at the soft palate (confirmed by DISE); patient willingness to undergo implantation and to participate in device activation and follow‑up; device implantation per FDA labeling and clinical protocols.AHI in moderate‑to‑severe range (trial medians ~29); BMI and AHI per device labeling

    STAR and other HNS studies required polysomnography‑documented AHI and DISE; procedure‑related serious adverse events were uncommon (≤2% in STAR).

    TPNS (remedé) — trial-aligned coverage notes

    Evidence for TPNS (remedē) in CSA is limited and mixed; trials enrolled patients with CSA (often with comorbid heart failure) and used specific AHI/CAI thresholds:

    TPNS candidate criteria (trial-like): Polysomnography‑confirmed central sleep apnea meeting trial thresholds (eg, AHI ≥ 20 in pivotal trial); patient medically stable for the required period and having received appropriate guideline‑recommended therapy; willingness and ability to tolerate implantation and follow‑up per trial protocols; documented prior therapy attempts as applicable.AHI ≥ 20 in pivotal trial

    Costanzo et al. randomized trial demonstrated significantly higher proportion achieving ≥50% AHI reduction at 6 months (51% vs 11%), but pooled and long‑term comparative evidence is limited; evidence quality rated very low to insufficient for definitive conclusions.

    Implantable neurostimulation — evidence and limitations

    Implantable phrenic nerve neurostimulation (remedē) — evidence summary

    Remedē trial findings: Randomized manufacturer‑sponsored pivotal trial (Costanzo et al.) showed a significantly greater proportion of treated patients achieving ≥50% reduction in AHI at 6 months (51% treatment vs 11% control); pooled analyses and follow‑ups report improvements in AHI, CAI, quality‑of‑life measures and some reductions in HF‑hospitalization, but average AHI often did not normalize to mild disease and long‑term comparative effectiveness and safety data remain limited.

    Hayes and ECRI assessments rate evidence as low/very‑low quality and call for additional RCTs and long‑term outcome data; prior authorization should document trial‑like criteria.

    LAUP — insufficient evidence / safety concerns

    Laser-assisted uvulopalatoplasty (LAUP) — evidence summary

    LAUP evidence: Existing studies and systematic reviews report mixed efficacy with some uncontrolled series noting improvement but meta‑analyses and reviews demonstrating modest success, substantial heterogeneity, and a high complication rate; some analyses report that LAUP can worsen OSA in a subset of patients.

    Reported complication rate averages are high (eg, ~256 complications per 1,000 procedures in systematic review); overall evidence insufficient to conclude effectiveness and safety concerns suggest avoiding LAUP as a stand‑alone OSA therapy.

    Lingual suspension/tongue fixation — limited and heterogeneous evidence

    Lingual suspension / tongue base procedures — evidence summary

    Tongue base procedures evidence: Available systematic reviews, case series, and comparative observational studies report variable success rates across techniques (modified TBS often showing higher success than older Repose-based techniques); pooled overall complication rates approximate 12.8% with heterogeneity across studies; evidence is largely observational with limited long‑term outcomes.

    Suture/device failures and anchor complications have been reported; patient selection and concurrent multilevel procedures influence outcomes.

    Hyoid myotomy/suspension — insufficient high-quality evidence

    Hyoid myotomy/suspension — evidence summary

    Hyoid surgery evidence: Case series and small nonrandomized studies demonstrate reductions in AHI and ESS in selected cohorts and when combined with other procedures, but evidence for isolated hyoid myotomy/suspension is limited by small sample sizes, lack of control groups, and short follow‑up; current evidence is insufficient to establish efficacy as a stand‑alone procedure.

    Product briefs and systematic reviews classify evidence as inconclusive.

    Uvulectomy — insufficient evidence

    Uvulectomy — evidence summary

    Uvulectomy evidence: Published peer‑reviewed literature is inadequate to support uvulectomy as a stand‑alone treatment for OSA; available evidence is insufficient to demonstrate effectiveness.

    Hayes review and policy assessment found insufficient data for standalone uvulectomy.

    Palatal implants — limited efficacy and mixed RCT results

    Palatal implants — evidence summary

    Palatal implants evidence: Randomized trials and meta‑analyses report small‑to‑moderate improvements in AHI and ESS for mild‑to‑moderate OSA, but some RCTs fail to show superiority over placebo and overall evidence is limited by small sample sizes and short follow‑up; effectiveness is therefore limited and conditional in select patients.

    Some uncontrolled series report objective 'cure' rates ~34% but NICE guidance and systematic reviews recommend caution due to limited evidence.

    Surgical/device therapies for OSA — general coverage framing

    Covered when ALL of the following are met (per referenced guideline consensus):

    General prerequisites: Patient has obstructive sleep apnea; conservative noninvasive therapy (CPAP or oral appliance when appropriate) has been tried and documented and was not tolerated or was ineffective; surgical or device therapy is anatomically appropriate for the site of obstruction; device‑ or procedure‑specific selection criteria (including AHI/BMI limits and anatomic assessments) for the chosen therapy are met; informed consent documents expected benefits and risks.documented CPAP/oral appliance failure or intolerance when applicable

    Derived from AASM and AAO‑HNS guidance; prior authorization should document trials and objective testing.

    Radiofrequency ablation (RFA) — conditional coverage

    Considered for patients with mild to moderate OSA who cannot tolerate or decline positive airway pressure or oral appliances, when site of obstruction is appropriate and patient understands limited/low-quality evidence:

    RFA criteria: Indication: mild‑to‑moderate OSA with palatal and/or tongue‑base obstruction; prior conservative therapy attempted, declined, or not tolerated; informed consent acknowledging limited/low‑quality long‑term evidence and variable efficacy; procedure performed by a qualified surgical provider with documentation of pre/post objective testing where feasible.AHI generally in mild‑to‑moderate range per study criteria

    AASM notes RFA is an option with very low‑quality evidence; selection and counseling essential.

    Palatal implants — limited/conditional

    May be considered only for select patients with mild OSA intolerant of CPAP/oral appliance, with counseling on limited efficacy:

    Palatal implant criteria: Patient has mild OSA with suspected retropalatal obstruction; prior CPAP and/or oral appliance intolerance or failure documented; patient counseled regarding limited magnitude of expected benefit and need for further evidence; procedure performed by credentialed provider with pre/post objective testing when possible.AHI typically in mild range per cited trials

    NICE and systematic reviews advise caution; RCTs show small effects and mixed superiority vs placebo.

    Transoral Robotic Surgery (TORS) — selective coverage with documentation

    Considered for select patients (typically as part of multilevel surgery) when conservative therapy failed and patient anatomy suggests benefit; provider must document expected benefit and counseling on complication rates:

    TORS criteria: Patient selection demonstrates tongue‑base or hypopharyngeal obstruction amenable to transoral resection; documented failure or intolerance of CPAP and/or oral appliance therapy; informed consent addressing limited randomized evidence and potential morbidity; pre‑ and post‑operative objective testing (attended PSG) documented; typically performed as part of multilevel surgical approach with experienced surgical team.improvement expectations vary; reported pooled success rates ~48–69% in nonrandomized series

    Systematic reviews show variable complication rates (average reported ~22%) and low-level evidence; documentation must justify multilevel approach.

    Distraction Osteogenesis for Maxillary Expansion (DOME) — investigational/limited

    Not established — considered investigational due to insufficient evidence of effectiveness in adults:

    DOME criteria: Distraction osteogenesis for maxillary expansion (DOME) is investigational for adult OSA because randomized controlled trials and long‑term outcomes are lacking; if considered in exceptional cases, require documentation of CPAP intolerance, specific anatomic indication (eg, narrow palatal arch), and detailed informed consent acknowledging investigational status.none established

    Published series are uncontrolled and limited; policy classifies DOME as not established for adult OSA.

    Device- and therapy-specific selection criteria

    Therapies recommended or considered when ALL of the following device- or patient-specific criteria are met (per guidelines and FDA indications):

    Inspire UAS adult implant candidacy: Patient meets device‑specific AHI and BMI criteria per FDA labeling (eg, original AHI ≥20 and ≤65; FDA expansion permits lower AHI threshold down to ≤15 and upper AHI up to 100 in selected cases; BMI upper limit expanded to 40 in updated labeling), has failed or cannot tolerate PAP therapy, and does not have complete concentric collapse at the soft palate level as confirmed by DISE; device implantation follows FDA guidance and documented pre/post testing.AHI and BMI per FDA‑expanded indications

    Prior authorization should document FDA indication criteria and prior conservative therapy attempts.

    remedē phrenic nerve stimulation candidacy: Patient has moderate to severe central sleep apnea meeting device PMA criteria and trial‑like inclusion thresholds, is medically stable, has received guideline‑recommended prior therapy where applicable, and is willing to undergo implantation and follow-up per protocol.moderate to severe CSA per device PMA (eg, AHI ≥20 in trials)

    Evidence quality is limited; prior authorization should document trial‑like criteria and medical stability.

    Oral appliance or positional therapy candidacy: For appropriate patients with mild to moderate OSA (eg, AHI <30), consider custom mandibular advancement devices or positional therapy (eg, non‑supine AHI <20 positional device candidates) as alternatives to PAP, with treatment provided by qualified dental/sleep providers and objective follow‑up testing.AHI <30 for MAD; non‑supine AHI <20 for positional devices

    VA/DoD and other guidelines provide conditional recommendations for these alternatives in selected patients.

    Surgical options for refractory or selected patients: Consider HNS evaluation for patients historically meeting guideline thresholds (eg, AHI 15‑65 and BMI <32 per some guidelines) who cannot adhere to PAP, and consider MMA for appropriately selected severe OSA patients intolerant of other therapies; apply device labeling and updated FDA criteria when making decisions.AHI and BMI per guideline/device criteria (eg, historical HNS guideline AHI 15‑65, BMI <32)

    Recent FDA expansions may change thresholds; verify current device labeling and document rationale.

    The policy identifies multiple devices and procedures as unproven or not medically necessary for the treatment of obstructive or central sleep apnea when there is insufficient quality evidence of efficacy or when safety concerns have been raised. Examples explicitly listed include positional OSA devices, nasal dilators, intranasal expiratory resistance valves, removable oral appliances for central sleep apnea (CSA), prefabricated (ready‑made) oral appliances, non‑surgical electrical muscular training, mandibular vertical repositioning devices (e.g., Slow Wave), morning repositioning devices, epigenetic and Advanced Lightwire Functional (ALF) appliances, and a set of surgical procedures (including LAUP, lingual suspension, isolated hyoid myotomy, stand‑alone uvulectomy, palatal implants, radiofrequency ablation, TORS, and DOME).

    For certain procedures there are specific safety and evidence concerns noted: LAUP has inconsistent efficacy in published series and systematic reviews and has been associated with a high complication rate (reported as ~256 complications per 1,000 procedures in pooled reviews), raising both effectiveness and safety concerns; palatal implants show mixed RCT results with only small‑to‑moderate treatment effects in some studies and are discouraged by some guidance bodies; and removable oral appliances for CSA have no identified relevant evidence supporting their use because CSA is neurogenic rather than primarily an anatomic obstruction.

    The policy emphasizes that FDA clearance or approval is informational only and not by itself sufficient to establish coverage; absent convincing evidence of clinical benefit and appropriate indication, devices or procedures may be considered investigational or not medically necessary. Finally, providers should confirm individual member benefit plan terms because member‑specific coverage rules govern and may differ from the standard policy.

    The evidence base does not support use of removable oral appliances for treatment of central sleep apnea (CSA). CSA is a disorder of respiratory drive rather than a primary anatomic obstruction, and the literature review identified no relevant studies demonstrating benefit from removable oral appliances in CSA.

    Similarly, prefabricated (ready‑made) oral appliances and mandibular vertical repositioning devices lack quality evidence demonstrating safety or efficacy for obstructive sleep apnea. Comparative data favor custom, titratable mandibular advancement devices over ready‑made devices; prefabricated devices are not recommended by evidence‑based guidelines and are considered unsupported for coverage.

    When requesting coverage for oral appliances, documentation should therefore reflect an appropriate indication (obstructive, not central, sleep apnea), selection of a custom/titratable device when indicated, and confirmation of member benefit terms, since unsupported device classes may be denied.

    The policy explicitly calls out several appliance classes for which no quality evidence supports efficacy in OSA: mandibular vertical repositioning devices (e.g., Slow Wave), morning repositioning devices, epigenetic appliances, and Advanced Lightwire Functional (ALF) appliances. The literature search did not identify rigorous trials or guideline endorsements for these therapies.

    Because these device classes lack peer‑reviewed evidence of benefit, they are considered unsupported and may be categorized as not medically necessary if submitted for OSA treatment. Providers should avoid relying on these devices as alternatives to established therapies without stronger evidence and proper prior authorization documentation.

    Hypoglossal nerve stimulation (HNS/UAS) has evidence supporting use in a specific pediatric subgroup—adolescents with Down syndrome—where published series and trials report objective improvements in AHI and quality of life after implantation following adenotonsillectomy and PAP attempts. However, the policy cautions that these results cannot be extrapolated to pediatric patients without Down syndrome; pediatric studies outside the Down syndrome population are limited or absent.

    For pediatric HNS candidacy the policy references trial‑like selection (e.g., AHI and RDI thresholds, BMI limits, and absence of concentric palatal collapse) and reiterates that device labeling and FDA pediatric indications must be confirmed prior to authorization. Providers must document prior therapy attempts, anatomical suitability (including DISE when required), and verify member plan terms.

    Several soft‑palate and related procedures are identified as having insufficient high‑quality evidence to support routine coverage as stand‑alone treatments for OSA. These include Laser‑Assisted Uvulopalatoplasty (LAUP), stand‑alone uvulectomy, and some types of palatal implants and minimally invasive palatal surgeries.

    Specifically for LAUP, systematic reviews and meta‑analyses report mixed efficacy with potential for worsening of OSA in some patients and a high complication burden; therefore LAUP should be used only with caution in select patients and is generally considered unsupported for routine coverage without stronger evidence. NICE guidance similarly concluded that palatal implants lack adequate evidence of efficacy and recommended they not be used for OSA, reinforcing the need for caution and informed consent when considering palatal procedures.

    Because of these limitations, the policy treats these procedures as investigational or not medically necessary for most OSA indications and requires thorough documentation if considered for exceptional cases.

    Some procedures and device indications include explicit contraindications or selection exclusions that affect coverage. Notably, the Inspire Upper Airway Stimulation (HNS/UAS) device labeling requires the absence of complete concentric collapse at the soft palate (as assessed by drug‑induced sleep endoscopy) for candidacy; presence of complete concentric collapse therefore excludes patients from being appropriate candidates per device labeling.

    Additionally, HNS selection criteria referenced in the policy require confirmation of prior PAP failure or intolerance, adherence to device AHI and BMI ranges per FDA labeling or expanded indications, and documented anatomic suitability. Providers must verify these device‑specific constraints and include required objective testing and DISE documentation when seeking authorization.

    Coverage decisions under this policy are subject to the member‑specific benefit plan and any applicable federal or state mandates. The policy is intended to assist interpretation of standard UnitedHealthcare plans, but in the event of conflict the member‑specific benefit plan governs. Prior authorization determinations will require submission of medical records and objective documentation to demonstrate that device‑ or procedure‑specific selection criteria and prior therapy requirements have been met.

    Implantable phrenic nerve neurostimulation for central sleep apnea (e.g., the remedē system) is described as having an evidence base that is limited in quantity and quality. Technology assessments and systematic reviews characterize the body of evidence as very‑low to low quality, citing small trials, short follow‑up, potential biases, and an uncertain clinical impact, particularly for patients with heart failure.

    Although randomized and pooled analyses report statistically significant reductions in AHI/CAI and greater proportions of patients achieving large relative reductions in AHI, average AHI often did not normalize and long‑term comparative data on morbidity and mortality are lacking. Consequently, implantable neurostimulation for CSA is considered unproven or not medically necessary in many contexts unless trial‑like inclusion criteria are met and documented for select, investigational pathways.

    The policy reiterates that prefabricated (ready‑made) oral appliances and mandibular vertical repositioning devices lack adequate evidence of safety or efficacy for OSA. These device classes are therefore listed as unsupported and may be denied as not medically necessary when submitted for OSA treatment.

    Providers should prescribe and document use of custom, titratable oral appliances by qualified dental and medical teams when oral appliance therapy is indicated, and include objective follow‑up testing to demonstrate treatment effect.

    Interventions for which the policy found no quality or insufficient evidence are generally categorized as not medically necessary or investigational. This includes a broad set of non‑CPAP devices (see exclusions) and surgical interventions listed as unproven (e.g., LAUP, uvulectomy, palatal implants, certain tongue base and hyoid procedures, TORS, DOME).

    The policy notes that even when devices have regulatory clearance or approval, such clearance alone does not establish clinical benefit for coverage. Authorization requires documentation that the clinical scenario and patient selection meet evidence‑based or device‑specific criteria; otherwise, lack of supportive evidence may lead to denial or investigational classification.

    Provider Requirements, Prior Authorization & Documentation

    Prior Authorization

    Reference codes for PA requests

    Reference codes to include with prior authorization requests: HCPCS codes for oral appliances and positional devices (E0486, E0485, E0530, A7049), custom oral appliance coding clarification (K1027), neurostimulation device and lead/pulse generator codes (L8679, L8680, L8686), CPT/HCPCS codes used for phrenic nerve stimulator programming and interrogation (93150, 93151, 93152, 93153), and implantation/nerve stimulator procedure codes (64582, 64583, 64584). Also consider procedure and device codes listed in the policy (0964T, 0965T, 0966T, 21142, 21199, 21206, 21685, 33276–33288, 41512, 41530, 41599, 42140, 42145, 42299, 64570, S2080, S2900) when applicable.

    • E0486 (custom fabricated oral appliance)
    • E0485 (prefabricated oral device)
    • K1027 (custom oral device without fixed hinge)
    • E0530 (electronic positional therapy)
    • A7049 (EPAP valve)
    • L8679 / L8680 / L8686 (implantable neurostimulator device/electrodes)
    • 93150–93153 (phrenic nerve stimulator programming/interrogation)
    • 64582–64584 (hypoglossal nerve neurostimulator implantation/revision/removal)
    • 0964T–0966T (jaw expansion oral prosthesis codes)
    • S2080, S2900 (LAUP, robotic surgery technique codes)
    Prior Authorization

    Prior authorization likely for hypoglossal nerve stimulator implantation

    Implantation of a hypoglossal nerve stimulator (Inspire UAS) generally requires prior authorization; the policy frames HNS as a second-line, implantable surgical option for moderate-to-severe OSA in patients intolerant or unwilling to use PAP.

    • Device is FDA‑approved Inspire UAS and is intended for patients unable or unwilling to use PAP
    • HNS was evaluated as second‑line after PAP failure or intolerance in trials (STAR and others)
    Documentation Required

    Prescribe custom, titratable oral appliances with documented follow-up

    When prescribing oral appliance therapy (OAT), use custom, titratable devices fitted by a qualified dentist with documented follow-up and objective testing; the AASM and AADSM recommend physician-dentist collaboration and follow-up sleep testing to confirm efficacy.

    • Face‑to‑face medical evaluation and diagnosis by a physician/APP required prior to OAT (AASM/AADSM/AAO‑HNS)
    • Qualified dentist should fit a custom, titratable appliance rather than non‑custom devices
    • Document follow‑up sleep testing and periodic collaborative visits between dentist and sleep physician
    Prior Authorization

    Authorization requires documented AHI and prior therapy

    Authorization for implantable devices requires documentation of pre‑implant AHI (trial‑specific thresholds noted: remedē pivotal trial AHI ≥ 20; Inspire/STAR included moderate‑to‑severe OSA with median baseline AHI ~29) and documentation of prior guideline‑recommended therapy attempts (e.g., CPAP failure/intolerance).

    • Provide attended polysomnography AHI supporting device inclusion threshold (e.g., remedē AHI ≥20; STAR median AHI ~29)
    • Document prior PAP therapy and evidence of failure, intolerance, or refusal
    Prior Authorization

    Prior authorization documentation for remedē (implantable TPNS)

    Prior authorization for implantable phrenic nerve neurostimulation (remedē) should document the CSA indication with baseline full‑night PSG AHI meeting trial criteria (pivotal trial required AHI ≥ 20), medical stability and prior appropriate guideline‑recommended therapy, and willingness to tolerate implantation and follow‑up per study-like inclusion.

    • Baseline polysomnography demonstrating AHI ≥ 20 as used in the remedē pivotal trial
    • Documentation of medical stability for ≥30 days and prior guideline‑recommended treatments
    • Evidence of informed consent and capacity to comply with implantation and follow‑up procedures
    Step Therapy

    Document prior noninvasive therapy attempts before invasive options

    Providers must document trials and failure/intolerance of noninvasive therapies (CPAP or oral appliances) before surgery or implantable device consideration; guidelines (AASM, AAO‑HNS) indicate surgery is an option when noninvasive treatments have failed or are not tolerated.

    • Record attempts and documented failure or intolerance of PAP and, when applicable, oral appliance therapy prior to surgical referral
    • Include objective measures (PSG results) and clinical notes describing intolerance or non‑adherence
    Prior Authorization

    Confirm FDA indications and prior therapy in PA documentation

    Prior authorization should confirm that the patient meets FDA‑labeled indications and guideline selection criteria for implantable or specialty devices (for example, Inspire UAS AHI/BMI limits and absence of complete concentric collapse), and that prior therapy attempts are documented.

    • Verify AHI and BMI meet device labeling (Inspire original and expanded indications)
    • Confirm absence of complete concentric palatal collapse (DISE) when required by device labeling
    • Document prior PAP failure/intolerance
    Note

    Verify member‑specific benefits and plan mandates

    Verify member‑specific benefit plan terms and any applicable federal or state mandates before submitting authorization requests; the policy is intended to guide UnitedHealthcare standard plans but the member's plan governs coverage.

    • Check the member specific benefit plan document for coverage rules and exclusions
    • Be aware that medical records may be requested and that plan terms override the policy when conflicts exist
    Step Therapy

    Document PAP trial before alternatives (OAT or surgery)

    PAP therapy (CPAP/APAP) should be trialed and documented prior to offering alternatives like oral appliance therapy or surgical options; OAT may be considered when PAP shows no efficacy, intolerance, or patient refusal.

    • Document therapeutic CPAP trial and objective efficacy data or documented intolerance/non‑adherence
    • If offering OAT as alternative, include documentation of PAP failure/intolerance or patient refusal
    Step Therapy

    Require CPAP trial before positional device coverage

    Evidence shows CPAP more effectively reduces AHI than positional devices; payers may require a CPAP trial before coverage for positional therapy and positional devices are generally for position‑dependent OSA.

    • Provide prior CPAP trial documentation when seeking coverage for positional devices
    • Include PSG demonstrating position‑dependent OSA (non‑supine AHI criteria as applicable)
    Step Therapy

    CPAP as first‑line; oral appliances for CPAP‑intolerant patients

    Guidelines recommend CPAP/APAP as first‑line therapy for most adult OSA patients; oral appliances are an alternative for patients intolerant of CPAP or who prefer alternatives and should be prescribed and overseen by a sleep physician.

    • Document CPAP/APAP prescription and trial results when applicable
    • If using oral appliance as alternative, include diagnosis by sleep physician and dentist collaboration per AASM/AADSM guidance
    Step Therapy

    HNS considered second‑line after PAP failure/intolerance

    Hypoglossal nerve stimulation is presented and evaluated as a second‑line therapy after PAP failure or intolerance in multiple studies and guideline statements; authorization should reflect prior PAP attempts.

    • Document prior PAP failure or intolerance and attempts to improve adherence
    • Include trial‑like selection data (AHI/BMI, DISE findings) consistent with HNS candidacy
    Step Therapy

    Attempt conservative therapy before surgical/implantable options

    Noninvasive and guideline‑recommended therapies (e.g., CPAP/APAP) should be attempted and documented prior to consideration of surgical or implantable options; include objective testing and treatment notes.

    • Provide PSG data and documentation of noninvasive therapy trials
    • Include clinician notes describing intolerance, refusal, or inadequate efficacy
    Step Therapy

    Surgery generally requires prior CPAP/oral appliance trial

    Surgical interventions are typically considered second‑line after failure/intolerance of CPAP or oral appliance therapy per AASM and AAO‑HNS; prior conservative therapy documentation will be required for surgical authorization.

    • Document prior CPAP and/or oral appliance trials and reasons for surgical consideration
    • Include anatomical evaluation and procedure‑specific selection criteria for the planned surgery
    Note

    Document therapy escalation steps and prior trials

    Follow guideline-based escalation: consider mandibular advancement devices for mild‑to‑moderate OSA and evaluate hypoglossal nerve stimulation or surgery for selected patients who cannot adhere to PAP, ensuring documentation of prior trials.

    • When escalating, document prior conservative therapy attempts and rationale for next‑line therapy
    • Include objective PSG metrics and device‑specific candidacy data (AHI, BMI, DISE findings)
    Note
    Documentation Required

    Face‑to‑face evaluation and documentation of PAP failure/intolerance required

    Prior to devices or procedures, a face‑to‑face evaluation and diagnosis by a qualified sleep medicine physician (MD/DO) or APP under direct supervision is required; documentation of PAP failure/intolerance or refusal must be supplied when relevant.

    • Include face‑to‑face visit notes, sleep physician diagnosis, and documentation of PAP failure/intolerance/refusal
    • Medical records may be requested to determine medical necessity
    Documentation Required

    Document collaborative care and follow‑up testing for OAT

    For oral appliance therapy, document collaborative care between physician and dentist and record follow‑up sleep testing to confirm treatment efficacy per AASM and AADSM recommendations.

    • Document referrals and communication between the sleep physician and qualified dentist
    • Include results of follow‑up PSG or HSAT demonstrating efficacy or need for adjustment
    Documentation Required

    Document medical diagnosis, dental collaboration, and follow‑up for OAT

    Documentation for OAT should include a medical diagnosis of OSA by a qualified medical provider, referral to or collaboration with a qualified dentist for fitting, and objective follow‑up sleep testing to confirm efficacy.

    • Medical diagnosis and recommendation from a physician or APP
    • Dental fitting records and appliance specifications (custom, titratable)
    • Follow‑up PSG/HSAT results and periodic dental/sleep clinic visits
    Documentation Required

    Provide PSG‑confirmed AHI and prior CPAP documentation for device PA

    Prior authorization should include polysomnography‑confirmed AHI and documentation of prior CPAP failure, intolerance, or refusal; device trials and implant studies consistently required these diagnostic data.

    • Include attended PSG report with AHI and breakdown of central vs obstructive events
    • Provide clinical notes documenting prior CPAP attempts and reasons for failure or intolerance
    Documentation Required

    Clinical documentation required for remedē authorization

    For implantable phrenic nerve neurostimulation (remedē), include baseline full‑night PSG AHI, documentation of prior guideline‑recommended therapy attempts, evidence of medical stability, and device implantation/follow‑up data in authorization materials.

    • Baseline PSG AHI meeting trial criteria (e.g., AHI ≥20 in pivotal trial)
    • Confirmation of prior guideline‑recommended therapies and medical stability ≥30 days
    • Post‑implant follow‑up PSG and device interrogation/therapy programming notes
    Documentation Required

    Document pre/post PSG, BMI, and DISE for tongue base procedures

    For tongue base or lingual suspension procedures, include pre‑ and post‑operative PSG results, BMI, and drug‑induced sleep endoscopy findings when available; document prior CPAP intolerance and informed consent describing limited evidence and potential complications.

    • Pre‑ and post‑op PSG reports and ESS scores
    • BMI and DISE findings (if performed)
    • Informed consent noting limited long‑term evidence and device/suture failure risks
    Documentation Required

    Include objective pre/post PSG and validated symptom scores

    When seeking authorization for surgical or device interventions, include objective pre/post documentation similar to published studies: pre‑ and post‑procedure polysomnography and validated symptom scores (e.g., ESS, NOSE) to demonstrate effect.

    • Pre‑ and post‑procedure PSG data and comparison of AHI
    • Validated symptom questionnaires (ESS, NOSE) before and after intervention
    Documentation Required

    Document device‑specific FDA indication criteria are met

    Demonstrate that device‑specific FDA indication criteria are met in authorization requests (for example, Inspire UAS AHI and BMI ranges, absence of complete concentric palatal collapse, and prior PAP failure/intolerance).

    • Confirm AHI and BMI are within device labeling
    • Provide DISE documentation excluding complete concentric collapse when required
    • Show prior PAP failure/intolerance documentation
    Note

    Check member‑specific plan precedence prior to authorization

    Before using this policy for a coverage decision, check the member‑specific benefit plan document and any federal/state mandates; the member‑specific plan governs in case of conflict.

    • Verify member benefit plan language and applicable mandates
    • Prepare to supply medical records if requested for review
    Denial Risk

    Coverage subject to member‑specific plan terms

    Coverage is determined by the member‑specific benefit plan and applicable laws; inclusion of a service in this policy or the medical record documentation does not guarantee coverage.

    • Be prepared to provide medical records for review
    • Coverage decisions follow the member specific benefit plan and applicable law
    Denial Risk

    Oral appliances for CSA lack evidence — risk of denial

    Oral appliances are not supported for treatment of central sleep apnea (CSA); requests for OA to treat CSA may be denied due to lack of relevant evidence.

    • Do not submit OA PA for CSA without strong supporting evidence — policy states no relevant evidence for OA in CSA
    Denial Risk

    Unsupported devices (e.g., Slow Wave, ALF) may be denied

    Devices without quality evidence (mandibular vertical repositioning devices, morning repositioning, epigenetic appliances, ALF) are unsupported and may be denied as not medically necessary.

    • Avoid authorization for unsupported device classes; policy documents absence of quality evidence for these devices
    • Provide literature support if asserting medical necessity for such devices
    Denial Risk

    Missing prior therapy documentation may lead to denial

    Lack of documentation of prior guideline‑recommended therapy (for example, CPAP failure or intolerance) is a common reason for coverage denial; ensure prior therapy trials are clearly recorded.

    • Include notes on CPAP trial duration, adherence attempts, objective efficacy data, and reasons for discontinuation
    • Document efforts to improve PAP adherence prior to declaring failure
    Denial Risk

    Insufficient evidence for some procedures may trigger denial

    Procedures lacking sufficient high‑quality evidence (for example, LAUP) may be denied or considered investigational; include strong supporting data if requesting coverage.

    • Expect higher scrutiny and potential denial for LAUP and similar procedures with insufficient evidence
    • Attach peer‑reviewed evidence and justification when requesting coverage for such procedures
    Denial Risk

    Palatal implants — limited efficacy; denial risk

    Palatal implants have limited and mixed evidence and some RCTs failed to show superiority over placebo; lack of demonstrated efficacy may prompt noncoverage or medical necessity review.

    • Provide high‑quality evidence if requesting coverage for palatal implants; policy notes mixed results and limited effectiveness
    • Be prepared to document patient selection consistent with cited trials (mild‑to‑moderate OSA, retropalatal obstruction)
    Denial Risk

    Evidence limitations may lead to denial

    Evidence gaps—such as few randomized trials, small sample sizes, short follow‑up, and bias—are cited as reasons that may lead to coverage denial for many procedures and devices lacking robust evidence.

    • Anticipate denial or investigational determinations when evidence is low quality, biased, or lacks long‑term outcomes
    • Supply robust comparative data when available to support a coverage request
    Denial Risk

    Device indication constraints must be met or coverage may be denied

    Confirm device indication constraints (e.g., Inspire UAS requires absence of complete concentric collapse at soft palate and prior PAP failure/intolerance); failure to meet these constraints may result in noncoverage.

    • Provide DISE documentation and prior PAP trial evidence when seeking UAS coverage
    • Ensure documented AHI/BMI are within device labeling
    Note

    Member‑specific plan terms govern coverage — verify before PA

    Member‑specific benefit plan terms govern coverage and may differ from this standard policy; verify plan language to avoid denied authorizations based on plan exclusions or differing criteria.

    • Check member plan for exclusions or differing medical necessity criteria before submitting PA
    • If conflict exists, the member specific benefit plan document governs

    Applicable Codes, Thresholds and Billing Guidance

    Applicable Codesmixed
    0964TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; single arch, without mandibular advancement mechanism.
    0965TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, non-fixed hinge mechanism.
    0966TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, fixed hinge mechanism.
    21142Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft.
    21199Osteotomy, mandible, segmental; with genioglossus advancement.
    21206Osteotomy, maxilla, segmental (e.g., Wassmund or Schuchard).
    21685Hyoid myotomy and suspension.
    33276Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed.
    33277Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure).
    33278Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s).
    1–10 of 43
    1/5
    Coding Clarification / Dental exclusionmixed
    E0486Custom fabricated oral device/appliance used to reduce upper airway collapsibility, includes fitting and adjustment (coding clarification).
    D9947Dental service excluded from medical plan (example listed).
    D9948Dental service excluded from medical plan (example listed).
    D9949Dental service excluded from medical plan (example listed).
    Implantable hypoglossal nerve stimulatormixed
    device-specificInspire® hypoglossal nerve stimulation implant (implantation procedure and device codes to be used per billing guidance).
    Implantable neurostimulation (device/procedure)mixed
    Implantable phrenic nerve stimulation/remedē system — device/procedure codes not specified in this excerpt; see listed phrenic nerve stimulator CPT codes for insertion, interrogation, removal (e.g., 33276–33288, 93150–93153).
    LAUPmixed
    S2080Laser-assisted uvulopalatoplasty (LAUP).
    Tongue base procedures and suspensionsmixed
    41512Tongue base suspension, permanent suture technique.
    41530Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session.
    41599Unlisted procedure, tongue, floor of mouth.
    S2900Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure).
    Hyoid myotomy/suspensionmixed
    21685Hyoid myotomy and suspension.
    K981677AIRvance / tongue suspension system referenced in FDA approvals (see device listings).
    Uvulectomymixed
    42140Uvulectomy, excision of uvula.
    42145Palatopharyngoplasty (e.g., uvulopalatopharyngoplasty).
    Palatal implantsmixed
    P040417Pillar Palatal Implant System (referenced via FDA 510(k) K040417).
    Palatal implant device/procedure codes not otherwise specified in this excerpt.
    FDA 510(k) device clearances referencedmixed
    K180608Lunoa System (NightBalance) 510(k) Premarket Notification - positional therapy device.
    K180619Bongo intranasal appliance 510(k) approval.
    FDA device clearances and PMAs referencedmixed
    K180608Lunoa System 510(k) PMN.
    K180619Bongo intranasal appliance 510(k).
    K982717Somnoplasty System 510(k).
    K030108ArthroCare ENT Coblator Surgery System 510(k).
    DEN200018eXciteOSA de novo classification.
    K191320Slow Wave DS8 510(k).
    P160039remedē System PMA.
    K981677AIRvance Tongue Suspension 510(k).
    K040417Pillar Palatal Implant System 510(k).
    P130008Inspire Upper Airway Stimulation PMA and supplements.
    AHI / RDI thresholds
    Moderate OSA thresholdAHI or RDI ≥ 15 events/hour
    Severe OSA thresholdAHI > 30 events/hour
    Hypoglossal device AHI selectionAHI ≥ 15 and ≤ 100 events/hour for implantable hypoglossal stimulation in adults
    Hypoglossal device BMI
    Adult hypoglossal selection BMIBody Mass Index (BMI) ≤ 40 kg/m2
    BMI useBMI used as selection criterion alongside AHI and anatomic evaluation
    Device labelingDevice must be used in accordance with FDA guidelines which include BMI limits
    Adolescent hypoglossal device AHI
    Adolescent Down syndrome AHI/RDIAHI ≥ 10 and RDI ≤ 50 events per hour (ages 10–18) for hypoglossal device candidacy
    Pediatric BMI criterionBMI < 95th percentile for age (pediatric selection requirement)
    FDA pediatric indication noteFDA expanded pediatric indication applies to ages 13–18 with Down syndrome (AHI ≥10 and ≤50) per device labeling
    AHI inclusion thresholds
    remedē pivotal trial AHI inclusionAHI ≥ 20 events/hour required for enrollment in the remedē randomized pivotal trial
    STAR trial baseline AHISTAR trial median baseline AHI ≈ 29.3 events/hour (moderate-to-severe OSA population)
    Use in authorizationDevice trials required documented baseline polysomnography AHI per study thresholds
    AHI inclusion threshold (remedé RCT)
    remedē RCT enrollment AHIEligible patients had AHI ≥ 20 events/hour by attended polysomnography
    Trial eligibility contextPatients were required to be medically stable and have prior guideline-recommended therapy per study protocol
    Primary endpointProportion achieving ≥50% AHI reduction at 6 months used as primary effectiveness endpoint
    TOTS inclusion BMI threshold
    TOTS reported BMI inclusionBMI < 32 kg/m2 in the TOTS case series inclusion criteria
    TOTS AHI requirementIncluded patients with AHI > 15/hour per reported case series
    Study limitationsSmall sample size and lack of randomized comparison in TOTS reports
    Inspire UAS AHI and BMI thresholds
    Inspire original AHI rangeOriginal FDA indication: AHI ≥ 20 and ≤ 65 events/hour
    Inspire expanded AHI/BMI limitsFDA expanded indication: lower AHI limit ≤ 15, upper AHI limit up to 100, and BMI upper limit expanded from 32 to 40 kg/m2
    Pediatric Down syndrome indicationFDA pediatric indication (ages 13–18 with Down syndrome): AHI ≥ 10 and ≤ 50 events/hour, no complete concentric palatal collapse
    eXciteOSA AHI threshold
    eXciteOSA adult AHI indicationDevice description indicates use for adults (≥18 years) with AHI < 15
    Intended useDesigned for reducing snoring and mild OSA per device 510(k)/de novo information
    Evidence statusStudies are limited and comparative long-term efficacy data are lacking
    Lunoa (NightBalance) AHI threshold
    Lunoa positional indicationIndicated for adults with positional OSA having non‑supine AHI < 20
    FunctionRecords position and movement to assess and treat positional OSA (vibratory/position training) per 510(k)
    Regulatory noteLunoa received FDA 510(k) (K180608) for positional OSA use

    Clinical Background, Definitions & Evidence Context

    Obstructive sleep apnea (OSA) results from repetitive collapse of the upper airway during sleep, producing apneas and hypopneas that fragment sleep and increase daytime sleepiness and cardiometabolic risk. Central sleep apnea (CSA) reflects impaired respiratory drive rather than anatomic obstruction and is commonly associated with heart failure; treatment approaches differ and evidence for device‑based CSA therapies is more limited. Diagnosis is made by attended polysomnography or validated limited testing, and treatment selection should align with the underlying pathophysiology and available high‑quality evidence.

    Apnea / Hypopnea / AHI definitions
    Apnea definitionApnea: cessation of airflow lasting at least 10 seconds (≥90% reduction in sensor excursions compared to baseline)
    Hypopnea definitionHypopnea: reduction in airflow lasting at least 10 seconds with ≥30% airflow reduction and ≥3% oxygen desaturation or associated arousal
    AHI definitionApnea-Hypopnea Index (AHI): (number of apneas + hypopneas) × 60 / total sleep time (events/hour)
    OSA severity categories (mild/moderate/severe)
    Mild OSAAHI or RDI ≥ 5 and < 15 events/hour
    Moderate OSAAHI or RDI ≥ 15 and ≤ 30 events/hour
    Severe OSAAHI > 30 events/hour
    BMI categories (adult)
    UnderweightBMI < 18.5 kg/m2
    Normal weightBMI 18.5–24.9 kg/m2
    Obesity classesOverweight 25–29.9; Obesity class I 30–34.9; class II 35–39.9; class III ≥ 40 kg/m2
    Central Sleep Apnea (CSA) definition
    CSA definitionCentral Sleep Apnea: sleep-disordered breathing with decreased or absent respiratory effort often due to impaired ventilatory drive
    Clinical featuresAssociated with excessive daytime sleepiness, frequent nocturnal wakening, and can be due to hypoventilation or neurologic/medical causes
    Remedē contextImplantable phrenic nerve stimulation (remedē) targets moderate-to-severe CSA but evidence is limited
    Oral Appliance Therapy (OAT) definition
    OAT definitionNon-surgical intraoral devices worn during sleep to keep the airway open by mandibular advancement, tongue retention, or both
    Provider rolesSleep physician diagnoses OSA and qualified dentist provides/fits custom, titratable appliance with follow-up testing
    Side effectsKnown side effect: occlusal discrepancy; custom devices preferred over prefabricated devices
    EPAP definition
    EPAP definitionExpiratory Positive Airway Pressure (EPAP): a one-way nasal valve attached to the nostrils that creates positive end-expiratory pressure during exhalation
    MechanismIncreases upper airway resistance to collapse by generating end-expiratory pressure and tracheal traction
    Clinical evidenceRandomized trials show EPAP can reduce AHI versus sham in some patients but is inferior to CPAP long-term
    Hypoglossal nerve stimulation definition
    Hypoglossal stimulation definitionImplanted device (Inspire®) that senses respiration and stimulates the hypoglossal nerve to advance the tongue and open the airway
    Implant componentsSubcutaneous chest pulse generator with lead to hypoglossal nerve and respiration-sensing lead in chest
    Indication contextUsed for moderate-to-severe OSA in patients intolerant or unwilling to use PAP, per FDA labeling and trial criteria
    Custom titratable oral appliance (MAD/OAT) definition
    Custom titratable MAD/OATDentist-fitted mandibular advancement device with adjustable titration to improve airway patency; preferred over non-custom devices
    OversightPrescription by sleep physician and fitting by qualified dentist with follow-up PSG recommended
    Coding noteCustom devices referenced in coding (e.g., HCPCS E0486) in policy coding tables
    Intraoral awake neuromuscular electrical stimulation definition
    Intraoral awake stimulationNon-invasive intraoral device delivering electrical stimulation to tongue muscles while awake (e.g., Apone-Stim 400, eXciteOSA)
    Target populationReported benefit for snoring and mild OSA in small studies and systematic review
    Evidence limitationsLack of sham-controlled RCTs and long-term comparative data
    Maxillomandibular advancement (MMA) definition
    MMA definitionMaxillomandibular advancement (MMA): orthognathic surgery advancing maxilla and mandible to enlarge pharyngeal airway
    EffectivenessMeta-analyses report substantial AHI/RDI reductions and high proportions (~90%) with improvement post-MMA
    IndicationsConsidered for patients with craniofacial deficiency or severe OSA when other therapies fail or are contraindicated
    AHI as an outcome measure definition
    AHI as outcome measureAHI = number of apnea or hypopnea events per hour; primary efficacy outcome in trials (used to define severity and trial inclusion)
    Use in trialsUsed as enrollment criterion (e.g., STAR median baseline AHI ~29.3; remedē RCT AHI ≥20) and primary endpoint for efficacy
    LimitationsAHI reductions may not equate to normalization of AHI in all device studies; clinical outcomes and PROMs also assessed
    TPNS (remedé) definition
    TPNS (remedē) definitionTransvenous phrenic nerve stimulation (remedē System): implantable device stimulating the phrenic nerve to reduce central sleep apnea severity
    IndicationFDA-approved for moderate-to-severe CSA in adults (PMA P160039)
    Evidence summaryPivotal trial enrolled patients with AHI ≥20; studies show reductions in AHI/CAI but evidence described as very-low-quality overall
    HNS / UAS (Inspire) definition
    HNS / UAS (Inspire) definitionUpper Airway Stimulation: implantable hypoglossal nerve stimulator (Inspire®) that senses respiration and stimulates hypoglossal nerve to advance tongue
    Patient selectionUsed in patients with moderate-to-severe OSA intolerant of PAP and without complete concentric palatal collapse
    Regulatory statusFDA PMA granted; pivotal STAR trial demonstrated substantial median AHI reduction at 12 months
    Phrenic nerve stimulation / remedé System definition
    Phrenic nerve stimulation definitionImplantable transvenous neurostimulation that stimulates the phrenic nerve to reduce central apnea events (remedē System)
    Pivotal trial featuresRandomized pivotal trial required AHI ≥20 and assessed proportion with ≥50% AHI reduction at 6 months
    Safety/evidence noteEvidence limited; additional RCTs and long-term data needed to define clinical impact
    LAUP definition
    LAUP definitionLaser-Assisted Uvulopalatoplasty (LAUP): laser ablation/stiffening of soft palate to reduce snoring/OSA
    Evidence cautionInsufficient quality evidence and notable complication rates; may worsen OSA in some patients
    Clinical useFurther well-designed studies required before routine coverage
    Palatal implants definition (Pillar, Elevo)
    Palatal implants definitionSmall polyester inserts (e.g., Pillar, Elevo) placed in soft palate to stiffen tissue and reduce airway collapse
    Efficacy summaryRCTs and meta-analyses show small-to-moderate improvements in AHI/ESS for mild-moderate OSA; overall evidence limited
    Regulatory statusPillar system 510(k) cleared by FDA (K040417)
    Radiofrequency tissue volume reduction (RFTVR) definition
    RFTVR definitionRadiofrequency tissue volume reduction (RFTVR): low-intensity radiofrequency energy to shrink uvula, soft palate, and/or tongue (e.g., Somnoplasty, Coblation)
    Clinical noteMay provide short-term benefit for mild-to-moderate OSA; long-term randomized data limited
    Device examplesSomnoplasty, Coblation systems cleared by FDA for head and neck tissue coagulation
    Transoral Robotic Surgery (TORS) definition
    TORS definitionTransoral Robotic Surgery (TORS): robotic-assisted resection of tongue base/hypopharyngeal tissue for OSA, often as part of multilevel procedures
    Evidence statusSystematic reviews report variable success rates and notable heterogeneity; high-quality comparative trials lacking
    DocumentationOften considered for select patients with documented anatomy and prior therapy failure
    Distraction Osteogenesis for Maxillary Expansion (DOME) definition
    DOME definitionDistraction Osteogenesis for Maxillary Expansion (DOME): surgical expansion of maxilla via distractors to widen maxillary arch to improve airway
    Evidence conclusionInsufficient quality evidence for adult OSA; considered investigational pending RCTs and long-term outcomes
    When consideredIf used, requires documentation of CPAP intolerance and specific anatomic indications
    Upper Airway Stimulation (Inspire) definition
    Upper Airway Stimulation (Inspire) summaryImplantable hypoglossal nerve stimulator indicated for selected adults (and pediatric Down syndrome subgroup) with specified AHI and BMI ranges who have failed or cannot tolerate PAP and lack complete concentric palatal collapse
    MechanismSenses respiration and stimulates hypoglossal nerve to advance tongue, opening airway
    Trial evidenceSTAR trial (n=126) demonstrated median AHI reduction ~68% at 12 months
    remedé System definition
    remedē System summaryImplantable transvenous phrenic nerve stimulator indicated for moderate-to-severe central sleep apnea in adults (PMA P160039)
    Pivotal trial inclusionEnrolled patients with AHI ≥20; randomized trial showed 51% of treated patients achieved ≥50% AHI reduction vs 11% control at 6 months
    Evidence limitationsOverall evidence described as very low-quality; long-term comparative outcomes and impact on morbidity/mortality uncertain
    References — bibliographic citations and evidence sources
    Key references — clinical trials and guidelinesIncludes STAR (Strollo et al. 2014), Costanzo et al. (2016), meta-analyses on MMA, and guideline documents (AASM, AADSM, VA/DoD)
    Technology assessmentsHayes technology assessments and systematic reviews cited for HNS and remedē evaluations
    Device regulatory sourcesFDA PMA/510(k) documents referenced for Inspire, remedē, Lunoa, Pillar, and others

    Policy Updates and Revision Notes

    2026-01-01template updateLatest

    Template update applied to policy history; no clinical coverage changes specified.